Alkermes plc (ALKS) Stock: Price, Forecast & Analyst Target
Alkermes plc (ALKS) — MoonshotScore 35/100 (Weak band), calculated Nov 18, 2026. Price $46.18 (-1.43%), as of the Nov 19, 2026 trading session; market cap $7.76B. Expected results Feb 24, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 10.27× (cash as of Sep 30, 2026) · expected results Feb 24, 2027
Alkermes plc · ALKS · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Research dated 2026-09-13: Alkermes commercializes proprietary medicines for addiction and neuropsychiatric disorders while also earning manufacturing and royalty revenue from technology-platform relationships. Vivitrol, Aristada, Aristada Initio and Lybalvi must produce durable commercial economics while research spending rises and debt remains above available cash and investments.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Alkermes (ALKS)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a fragile balance sheet — yet price is running hot, well ahead of those stalled fundamentals; treat the move with suspicion, not chase. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Fragile; Valuation: Full; Growth Durability: Flat; Momentum: Surging.
- EPS beat 3 of the last 4 reports
- Altman Z 2.26 · Piotroski F 2
- ROE -0.0% · ROA -0.0% · current ratio 2.42 · earnings yield -0.0% · free-cash-flow yield 3.0%
Holding back: balance-sheet strain
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 38 | Weak | |
| 36 | Weak | |
| 36 | Weak | |
| 36 | Weak | |
| 35 | Weak | |
| 35 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $46.18 | |
| Change on the day | -1.43% | |
| 52-week range | $27.00–$55.67 | |
| Market capitalisation | $7.76B | — |
| Price / earnings (trailing) | 111.39 | |
| Shares traded on the day | 1.37M | |
| Beta (volatility vs the S&P 500) | 0.27 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
For the full year, we continue to expect VIVITROL net sales in the range of $460 million to $480 million.
Christian Todd Nichols · Statement from
For the full year, we continue to expect ARISTADA net sales in the range of $365 million to $385 million LYBALVI net sales were $95.9 million in the third quarter.
Christian Todd Nichols · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Alkermes (ALKS): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Klarman-style lens and Moon AI lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Alkermes (ALKS), and what does it report?
Short answer · as of
Alkermes is not a conventional generic-drug manufacturer. Its reported revenue blends sales of named proprietary treatments with manufacturing, manufactured-product and royalty income connected to technology platforms and pharmaceutical collaborations.
Research dated 2026-09-13.
That mix matters because consolidated revenue does not measure demand for a lone medicine or pipeline progress alone. It combines commercial performance in addiction and serious mental illness with partner-related economics, while research spending reflects continued work on neurological candidates.
What do the latest results show for Alkermes (ALKS)?
Research dated 2026-09-13.
The latest reported period delivered the strongest revenue in the presented quarterly series, reversing the preceding operating loss and returning the business to a modest profit. Operating cash flow also swung back into positive territory, while revenue and reported earnings exceeded analyst expectations.
The rebound coincided with selling and administrative expense retreating from its prior spike, even as research spending continued to rise. That expense pattern helped restore operating profitability, but the narrow net result shows that stronger revenue did not translate into a comparably large bottom-line cushion.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $480.13M Sep 30, 2026
- Latest quarter · R&D
- $121.12M Sep 30, 2026
- Latest quarter · SG&A
- $208.50M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $36.02M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $480.13M | $121.12M | $208.50M | $36.02M |
| Jun 30, 2026 | $496.01M | $112.92M | $217.60M | $18.38M |
| Mar 31, 2026 | $392.91M | $103.34M | $264.59M | −$48.28M |
| Dec 31, 2025 | $384.55M | $93.04M | $190.50M | $58.10M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $480.13M Nov 3, 2026
- Latest report · revenue estimate
- $463.48M Nov 3, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 3, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 3, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 3, 2026 | $480.13M | $463.48M | $0.0900 | −$0.0818 |
| Jul 28, 2026 | $496.01M | $457.38M | $0.7000 | −$0.0274 |
| May 5, 2026 | $392.91M | $363.06M | −$0.4000 | −$0.5700 |
| Feb 25, 2026 | $384.55M | $378.94M | $0.3400 | $0.4300 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Jun 2025 | $391M | $87M | $0.52 (diluted) |
| Sep 2025 | $394M | $83M | $0.49 (diluted) |
| Q4 FY2025 | $385M | $49M | $0.29 (diluted) |
| Q1 FY2026 | $393M | -$66M | -$0.40 (diluted) |
What are the financial strengths and risks for Alkermes (ALKS)?
Short answer
Cash and short-term investments were $755.46M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $93.48M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
High gross profitability and recurring positive operating cash flow provide meaningful internal funding capacity, and capital expenditure has remained modest relative to operating cash generation. Near-term liquidity ratios also indicate resources available against current obligations.
The balance sheet still carries substantially more debt than cash and investments, leaving Alkermes in a net-debt position. Cash has fallen sharply from its recent peak, profitability has been volatile, and rising research expense increases the damage that weaker sales from Vivitrol, Aristada or related commercial lines could cause to operating results.
Data-derived red flags
- Negative return on equity (-0.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Rich valuation — a P/E of 111.39 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $93.48M Sep 30, 2026
- Previous quarter · operating cash flow
- $145.18M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $93.48M | −$3.40M |
| Jun 30, 2026 | $145.18M | −$8.15M |
| Mar 31, 2026 | −$165.74M | −$4.09M |
| Dec 31, 2025 | $170.07M | $20,000 |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Alkermes (ALKS)?
Short answer · as of
The next earnings report is expected on Feb 24, 2027.
Research dated 2026-09-13.
The next earnings release needs to establish whether revenue can remain near its recent high, operating profit can stay positive and operating cash flow can avoid another reversal. Research spending, the normalization of selling and administrative expense, and the cash balance deserve attention because recent movements in those lines have been unusually large.
Longer-range analyst estimates embed sustained revenue and earnings expansion, making progress across the proprietary portfolio more important than an isolated earnings beat. Any disclosed financial or strategic effects from the recently reported material definitive agreement also warrant attention.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
For the full year, we continue to expect LYBALVI net sales in the range of $380 million to $400 million Looking ahead to next year, we expect gross to net adjustments for LYBALVI to be in the 45% range. We expect the benefits of expanded payer access to be reflected first in prescription volume, which we expect will continue to grow nearly 20% year-over-year with an acceleration in net sales growth expected to follow.
Christian Todd Nichols ·
For the full year, we continue to expect total LUMRYZ net sales of $350 million to $370 million of which Alkermes expects to record $315 million to $335 million reflecting the mid February close of the Avadel transaction.
Christian Todd Nichols ·
How does Alkermes compare with its peers?
Short answer
Alkermes's score ranks tied for 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Alkermes differs from a development-stage biotechnology company because marketed products already generate substantial revenue and operating cash flow. It also differs from a broad generic manufacturer: its economics are tied to branded treatments in addiction and serious mental illness, supplemented by manufacturing and royalty relationships built around proprietary technology platforms.
The resulting profile combines branded-drug gross profitability with the research intensity and earnings volatility associated with an active neurological pipeline. That combination makes commercial execution and development spending inseparable when assessing operating durability.
| Company | Price | Market value | Score |
|---|---|---|---|
| $102.00 Nov 18, 2026 | $6.67B | 96 5-pillar Nov 18, 2026 | |
| $66.12 Nov 18, 2026 | $9.99B | 90 5-pillar Nov 18, 2026 | |
| $127.16 Nov 18, 2026 | $8.30B | 88 5-pillar Nov 18, 2026 | |
| $85.57 Nov 18, 2026 | $34.8B | 87 5-pillar Nov 18, 2026 | |
| $14.85 Nov 19, 2026 | $12.4B | 77 5-pillar Nov 18, 2026 | |
| $28.96 Nov 18, 2026 | $6.02B | 74 5-pillar Nov 18, 2026 | |
| $13.99 Nov 18, 2026 | $2.43B | 70 5-pillar Nov 18, 2026 | |
| $21.88 Nov 18, 2026 | $7.62B | 66 5-pillar Nov 18, 2026 | |
| $58.52 Nov 18, 2026 | $9.26B | 51 5-pillar Nov 18, 2026 | |
| $4.69 Nov 18, 2026 | $2.33B | 47 5-pillar Nov 18, 2026 | |
| Alkermes (ALKS) — this page | $46.18 | $7.76B | 35 |
| $26.70 Nov 18, 2026 | $13.4B | 35 5-pillar Nov 18, 2026 | |
| $20.28 Nov 18, 2026 | $23.3B | 35 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $50.00 – $68.00
- Consensus target
- $58.70
- Median target
- $58.50
Consensus record · Captured .
Measured against a quoted price of $46.18 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 3, 2026
- Transactions
- 40
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 16
- Other transactions
- 24
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 426 Period end Sep 30, 2026
- Previous quarter · holders
- 439 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 28,703,354 |
| State Street Corp | 10,131,249 |
| Baker Bros. Advisors LP | 10,012,267 |
| Vanguard Portfolio Management LLC | 9,459,289 |
| Vanguard Capital Management LLC | 7,503,336 |
Tracked investors
Which of the 16 named investors we follow held ALKS in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ALKS in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Alkermes (ALKS)?
What Investors Ask About Alkermes (ALKS) — Healthcare
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How do Vivitrol and Aristada shape Alkermes revenue?
Vivitrol is the largest disclosed product revenue category, while Aristada and Aristada Initio form another major proprietary franchise. Their weight makes Alkermes sensitive to commercial performance in addiction treatment and schizophrenia alongside its partner-related revenue streams.
Why does Alkermes report manufacturing and royalty revenue alongside medicine sales?
Alkermes provides proprietary technology platforms to pharmaceutical partners and maintains collaboration relationships. Those arrangements create manufacturing, manufactured-product and royalty economics beyond sales of Alkermes-branded medicines.
What changed in Alkermes after its recent operating loss?
Revenue rose to the strongest level in the presented quarterly series, the operating result returned to profit and operating cash flow recovered. Selling and administrative expense receded from its prior surge, although research spending continued upward.
Does Alkermes cash cover its debt?
Cash and investments remain below total debt, leaving the company in a net-debt position. Current liquidity is supported by positive short-term ratios, but the cash balance has declined materially from its recent peak.
What is the ALKS stock price today?
The last price recorded for Alkermes plc (ALKS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ALKS price target?
The analyst consensus price target for Alkermes plc (ALKS), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 79 figures on this page — 2 from SEC filings and earnings calls, 70 from Financial Modeling Prep (FMP), 3 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold ALKS
Funds in our ETF coverage that list ALKS among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| iShares Neuroscience and Healthcare ETF (IBRN) | 4.21% |